StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
21
Publishing Date
2022 - 06 - 06
20
2022 - 06 - 05
1
Sector
Communications
1
Health technology
18
Manufacturing
1
Tags
Acquisition
3
Alliances
3
America
3
Asco
13
Automotive
3
Biotech-bay
4
Biotech-beach
5
Biotechnology
5
Cancer
11
Collaboration
4
Commercial
4
Conference
28
Corporation
3
Designation
7
Diabetes
5
Disease
6
Drug
3
Energy
5
Events
4
Fda
4
Genetown
6
Grant
3
Group
5
Growth
11
Health
4
Index
3
International
3
Life
4
Management
5
Market
29
Media
3
N/a
253
Nasdaq
3
Offering
4
People
6
Pharm-country
3
Pharmaceutical
5
Phase 1
6
Phase 2
3
Phase 2b
4
Phase 3
5
Platform
4
Positive
7
Presentation
5
Program
8
Report
11
Research
24
Results
17
Risk
3
Security
3
Services
4
Sessions
4
Solar
5
Solutions
4
Technology
6
Therapeutics
13
Therapy
3
Train
3
Treatment
10
Trial
21
Entities
Adicet bio, inc.
1
Applied genetic technologies corporation
1
Arbutus biopharma corporation
1
Arcutis biotherapeutics, inc.
1
Assembly biosciences, inc.
1
Bristol-myers squibb company
2
Checkpoint therapeutics, inc.
1
Chemocentryx, inc.
1
Effector therapeutics inc
1
Eli lilly and company
1
Enlivex therapeutics ltd.
1
Fortress biotech, inc.
1
Illumina, inc.
1
Immunitybio inc
1
In8bio inc
1
Johnson & johnson
1
Orange
1
Otonomy, inc.
1
Phio pharmaceuticals corp.
1
Puma biotechnology inc
1
Radius health, inc.
1
Sanofi
1
Vertex pharmaceuticals incorporated
1
Veru inc.
1
Zealand pharma a/s
1
Symbols
ABUS
1
ACET
1
AGTC
1
ARQT
1
ASMB
1
BMY
2
CCXI
1
CKPT
1
EFTR
1
ENLV
1
FBIO
1
FNCTF
1
IBRX
1
ILMN
1
INAB
1
JNJ
1
LLY
1
OTIC
1
PBYI
1
PHIO
1
RDUS
1
SNY
1
SNYNF
1
VERU
1
VRTX
1
ZEAL
1
Exchanges
Nasdaq
19
Nyse
4
Crawled Date
2023 - 12 - 12
15
2023 - 12 - 11
18
2023 - 10 - 24
17
2023 - 10 - 23
16
2023 - 09 - 26
16
2023 - 09 - 11
16
2023 - 06 - 05
20
2023 - 05 - 25
23
2022 - 12 - 08
20
2022 - 06 - 06
21
2022 - 05 - 23
15
2022 - 03 - 16
15
2022 - 03 - 01
17
2022 - 02 - 28
15
2022 - 02 - 15
15
2022 - 01 - 18
16
2022 - 01 - 04
15
2021 - 12 - 16
16
2021 - 12 - 14
15
2021 - 12 - 13
28
2021 - 12 - 09
21
2021 - 12 - 06
24
2021 - 11 - 30
15
2021 - 11 - 16
18
2021 - 11 - 15
17
2021 - 11 - 09
15
2021 - 11 - 08
19
2021 - 11 - 03
19
2021 - 10 - 28
17
2021 - 10 - 27
15
2021 - 10 - 25
17
2021 - 10 - 20
16
2021 - 10 - 14
18
2021 - 10 - 13
19
2021 - 10 - 12
15
2021 - 10 - 07
19
2021 - 09 - 28
15
2021 - 09 - 13
27
2021 - 09 - 09
16
2021 - 09 - 08
20
2021 - 08 - 31
15
2021 - 07 - 27
16
2021 - 07 - 15
15
2021 - 07 - 07
15
2021 - 07 - 06
17
2021 - 06 - 28
22
2021 - 06 - 25
15
2021 - 06 - 24
15
2021 - 06 - 23
24
2021 - 06 - 16
16
2021 - 06 - 07
21
2021 - 05 - 12
15
2021 - 04 - 15
16
2021 - 04 - 12
16
2021 - 03 - 18
17
2021 - 03 - 15
15
2020 - 12 - 10
16
2020 - 12 - 09
20
2020 - 12 - 03
22
2020 - 12 - 01
23
Crawled Time
00:00
1
11:00
1
12:00
5
12:20
1
13:00
3
15:00
2
16:00
2
17:00
1
19:00
2
20:00
1
21:00
1
23:00
1
Source
investor.assemblybio.com
1
ir.chemocentryx.com
1
ir.radiuspharm.com
1
www.biospace.com
11
www.globenewswire.com
5
www.nantkwest.com
1
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Trial
crawled date :
2022 - 06 - 06
save search
Zealand Pharma Presents Data from Phase 1 Trial of Dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions and Announces Dapiglutide to Move into Phase 2 Trial for Obesity
Published:
2022-06-06
(Crawled : 23:00)
- globenewswire.com
ZEAL
|
$17.59
1.21%
-4.21%
|
Health Technology
|
30.59%
|
O:
-4.23%
H:
2.27%
C:
2.27%
sessions
obesity
pharma
trial
diabetes
phase 1
Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published:
2022-06-06
(Crawled : 21:00)
- globenewswire.com
FBIO
|
$1.79
1.7%
1.68%
240K
|
Health Technology
|
92.2%
|
O:
-2.74%
H:
15.65%
C:
13.41%
CKPT
|
$1.66
-1.78%
-1.81%
270K
|
Health Technology
|
27.07%
|
O:
-2.26%
H:
10.0%
C:
5.38%
trial
therapeutics
presentation
results
cosibelimab
IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022
Published:
2022-06-06
(Crawled : 20:00)
- biospace.com/
INAB
|
$1.02
4.05%
3.89%
180K
|
|
-62.26%
|
O:
-3.77%
H:
31.76%
C:
5.88%
inb-200
trial
asco
positive
phase 1
glioblastoma
Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers
Published:
2022-06-06
(Crawled : 19:00)
- biospace.com/
ENLV
|
$1.47
1.38%
1.36%
390K
|
Health Technology
|
-71.9%
|
O:
-0.19%
H:
1.75%
C:
-0.39%
health
trial
authorization
Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting
Published:
2022-06-06
(Crawled : 19:00)
- prnewswire.com
PHIO
|
$0.6542
-3.68%
40K
|
Health Technology
|
-14.18%
|
O:
-0.98%
H:
4.0%
C:
-5.2%
ph-762
melanoma
trial
asco
AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting
Published:
2022-06-06
(Crawled : 17:00)
- biospace.com/
OTIC
|
$0.077
|
Health Technology
|
-96.05%
|
O:
2.04%
H:
2.5%
C:
-1.5%
AGTC
|
$0.3936
1.23%
0.0%
|
Health Technology
|
-56.23%
|
O:
2.06%
H:
0.24%
C:
-1.95%
agtc-501
treatment
trial
GRAIL and England’s National Health Service (NHS) Present Trial Design for Largest Study of Multi-Cancer Early Detection Test at ASCO Annual Meeting
Published:
2022-06-06
(Crawled : 16:00)
- biospace.com/
ILMN
|
$118.305
0.52%
0.52%
1.9M
|
Health Technology
|
-49.23%
|
O:
2.16%
H:
0.32%
C:
-4.79%
test
service
health
trial
asco
designation
Clinical Catch-Up: NIH's COVID-19 Trial and All About ASCO
Published:
2022-06-06
(Crawled : 16:00)
- biospace.com/
JNJ
|
News
|
$144.77
0.22%
-0.01%
9.3M
|
Health Technology
|
-18.24%
|
O:
0.1%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-13.97%
|
O:
0.63%
H:
0.0%
C:
0.0%
covid-19
trial
asco
Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions
Published:
2022-06-06
(Crawled : 15:00)
- biospace.com/
VRTX
|
$393.1
-0.27%
-0.27%
880K
|
Health Technology
|
45.9%
|
O:
0.74%
H:
0.21%
C:
-1.27%
vx-880
sessions
trial
diabetes
phase 1
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Published:
2022-06-06
(Crawled : 15:00)
- biospace.com/
PBYI
|
$5.18
1.57%
1.54%
250K
|
Health Technology
|
120.94%
|
O:
0.85%
H:
2.54%
C:
1.27%
trial
asco
cancer
breast cancer
metastatic breast cancer
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published:
2022-06-06
(Crawled : 13:00)
- ir.radiuspharm.com
RDUS
|
$18.22
4.53%
4.28%
270K
|
Health Technology
|
182.26%
|
O:
1.01%
H:
4.6%
C:
0.92%
elacestrant
trial
group
phase 3
elascestrant
ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published:
2022-06-06
(Crawled : 13:00)
- ir.chemocentryx.com
CCXI
|
$51.99
-0.04%
|
Health Technology
|
127.13%
|
O:
7.73%
H:
1.8%
C:
-3.37%
ccx559
ongoing
trial
results
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published:
2022-06-06
(Crawled : 13:00)
- nantkwest.com
FNCTF
|
News
|
$11.0354
-20.84%
320
|
Communications
|
-7.81%
|
O:
0.17%
H:
0.0%
C:
0.0%
IBRX
|
$5.25
6.71%
6.29%
4.3M
|
Manufacturing
|
60.74%
|
O:
14.42%
H:
1.88%
C:
-4.29%
trial
cancer
pancreatic
bladder
Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
Published:
2022-06-06
(Crawled : 12:20)
- biospace.com/
ARQT
A
|
$10.23
1.29%
1.27%
2.2M
|
Health Technology
|
-50.84%
|
O:
4.65%
H:
1.24%
C:
-4.42%
topline
dermatitis
trial
positive
results
phase 3
Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab)
Published:
2022-06-06
(Crawled : 12:00)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-35.15%
|
O:
1.03%
H:
0.0%
C:
0.0%
opdivo
trial
plus
phase 3
nivolumab
Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection
Published:
2022-06-06
(Crawled : 12:00)
- investor.assemblybio.com
ASMB
|
$12.92
-11.02%
-12.38%
27K
|
Health Technology
|
633.33%
|
O:
4.55%
H:
1.45%
C:
-2.9%
treatment
hepatitis
virus
trial
infection
infections
phase 2b
chronic hepatitis b
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting
Published:
2022-06-06
(Crawled : 12:00)
- biospace.com/
ACET
|
$2.26
3.2%
3.1%
760K
|
Health Technology
|
-80.17%
|
O:
2.79%
H:
9.77%
C:
4.16%
adi-001
trial
phase 1
Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Published:
2022-06-06
(Crawled : 12:00)
- biospace.com/
BMY
|
$47.84
-0.87%
-0.02%
12M
|
Health Technology
|
-35.15%
|
O:
1.03%
H:
0.0%
C:
0.0%
treatment
opdivo
trial
plus
cancer
phase 3
nivolumab
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
Published:
2022-06-06
(Crawled : 12:00)
- globenewswire.com
ABUS
|
$2.79
-4.45%
-4.66%
710K
|
Health Technology
|
13.4%
|
O:
6.02%
H:
0.37%
C:
-6.23%
treatment
hepatitis
virus
trial
phase 2b
chronic hepatitis b
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published:
2022-06-06
(Crawled : 11:00)
- globenewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
147.75%
|
O:
3.83%
H:
0.0%
C:
0.0%
VERU
|
$1.165
-7.17%
-7.73%
2.5M
|
Health Technology
|
-91.1%
|
O:
10.2%
H:
0.0%
C:
0.0%
sabizabulin
trial
presentation
positive
cancer
phase 2b
prostate cancer
← Previous
1
2
Next →
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.